pergolide has been researched along with clozapine in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.00) | 18.7374 |
| 1990's | 8 (40.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 3 (15.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrieux, M; Besançon, R; Giros, B; Martres, MP; Pilon, C; Schwartz, JC; Sokoloff, P | 1 |
| George, SR; Guan, HC; Laurier, LG; Ng, G; Niznik, HB; O'Dowd, BF; Seeman, P; Sunahara, RK; Torchia, J; Van Tol, HH | 1 |
| Hamblin, MW; Monsma, FJ; Shen, Y; Sibley, DR; Ward, RP | 1 |
| Hamblin, MW; Jose, PA; Metcalf, MA; Monsma, FJ; Shen, Y; Sibley, DR | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Sen, S; Sinha, N | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fuller, RW; Snoddy, HD | 1 |
| Fenton, HM; Gerhardt, S; Leszczak, E; Liebman, JM | 1 |
| Diamond, BI; Klawans, HL; Koller, WC; Nausieda, PA; Weiner, WJ | 1 |
| Fici, GJ; Sethy, VH; VonVoigtlander, PF; Wu, H | 1 |
| Cabrera-Valdivia, F; Fernández-Lliria, A; Gasalla, T; Jiménez-Jiménez, FJ; Ortí-Pareja, M; Tallón-Barranco, A | 1 |
| Durso, R; Fernandez, HH | 1 |
| Armogida, M; Chiacchio, S; Colzi, A; Corsini, GU; DeMontis, MG; Maggio, R; Scarselli, M | 1 |
| Hundemer, HP; Oehlwein, C; Polzer, U; Schwarz, J; Storch, A; Trenkwalder, C; Winkelmann, J | 1 |
| Brann, MR; Burstein, ES; Davis, RE; Gao, Y; Hacksell, U; Knapp, AE; Ma, J; Nash, NR; Olsson, R; Pham, E; Weiner, DM; Wong, S | 1 |
| Bernardi, S; Meco, G | 1 |
1 review(s) available for pergolide and clozapine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
19 other study(ies) available for pergolide and clozapine
| Article | Year |
|---|---|
Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
Topics: Animals; Chlorides; CHO Cells; Cricetinae; Dopamine; Dopamine Agents; Dopamine Antagonists; Guanylyl Imidodiphosphate; Humans; Lithium; Lithium Chloride; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Dopamine D3; Sodium Chloride; Sulpiride; Transfection | 1992 |
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Topics: Amino Acid Sequence; Animals; Base Sequence; Binding, Competitive; Blotting, Northern; Brain; Cell Line; Cell Membrane; Cloning, Molecular; Dopamine; Humans; Kinetics; Molecular Sequence Data; Molecular Weight; Oligonucleotide Probes; Rats; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D5; RNA, Messenger; Sequence Homology, Nucleic Acid; Transfection | 1991 |
Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.
Topics: Amino Acid Sequence; Animals; Base Sequence; Binding, Competitive; Blotting, Northern; Brain Chemistry; Cell Line; Cloning, Molecular; DNA; GTP-Binding Proteins; Lysergic Acid Diethylamide; Molecular Sequence Data; Polymerase Chain Reaction; Psychotropic Drugs; Rats; Receptors, Serotonin; RNA; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Transfection | 1993 |
Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype.
Topics: Amino Acid Sequence; Animals; Base Sequence; Binding, Competitive; Cell Line; Cell Membrane; Cloning, Molecular; Cyclic AMP; Gene Expression; Kidney Tubules, Proximal; Lysergic Acid Diethylamide; Molecular Sequence Data; Oligodeoxyribonucleotides; Polymerase Chain Reaction; Radioligand Assay; Rats; Receptors, Serotonin; Recombinant Proteins; Serotonin; Transfection | 1993 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Corticosterone; Dopamine Antagonists; Drug Evaluation, Preclinical; Male; Neurosecretory Systems; Olanzapine; Pergolide; Pirenzepine; Quipazine; Rats; Rats, Inbred Strains; Serotonin Antagonists | 1992 |
Evidence for heterogeneous rotational responsiveness to apomorphine, 3-PPP and SKF 38393 in 6-hydroxydopamine-denervated rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Benzazepines; Clozapine; Ergolines; Humans; Hydroxydopamines; Male; Oxidopamine; Pergolide; Piperidines; Postural Balance; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior; Sympathectomy, Chemical | 1984 |
The pharmacological evaluation of pergolide mesylate as a potential anti-parkinson agent.
Topics: alpha-Methyltyrosine; Animals; Antiparkinson Agents; Apomorphine; Clozapine; Drug Interactions; Emetics; Ergolines; Guinea Pigs; Haloperidol; Humans; Hydroxydopamines; Male; Methyltyrosines; Pergolide; Rats; Stereotyped Behavior | 1980 |
D1 dopamine receptor activity of anti-parkinsonian drugs.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Apomorphine; Benzazepines; Benzothiazoles; Bromocriptine; Cells, Cultured; Cerebellum; Clozapine; Cyclic AMP; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Pergolide; Pramipexole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Tetrahydronaphthalenes; Thiazoles | 1997 |
Cenesthetic hallucinations in a patient with Parkinson's disease.
Topics: Aged; Clozapine; Female; Hallucinations; Humans; Levodopa; Parkinson Disease; Pergolide | 1997 |
Clozapine for dopaminergic-induced paraphilias in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Carbidopa; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Male; Paraphilic Disorders; Parkinson Disease; Pergolide | 1998 |
Reconstitution of functional dopamine D(2s) receptor by co-expression of amino- and carboxyl-terminal receptor fragments.
Topics: Animals; Apomorphine; Binding, Competitive; Clozapine; Colforsin; COS Cells; Cyclic AMP; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Membranes; Peptide Fragments; Pergolide; Quinpirole; Radioligand Assay; Rats; Receptors, Dopamine D2; Recombinant Fusion Proteins; Spiperone; Transfection; Tritium | 2000 |
High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Dyskinesias; Endpoint Determination; Female; Germany; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease; Pergolide; Psychotic Disorders; Retrospective Studies | 2005 |
Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist.
Topics: Animals; Antipsychotic Agents; Clozapine; Haloperidol; Humans; Mice; NIH 3T3 Cells; Pergolide; Plasmids; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Dopamine D4; RGS Proteins; Transfection | 2005 |
Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease.
Topics: Affect; Antidepressive Agents; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Antipsychotic Agents; Clomipramine; Clozapine; Delusions; Depressive Disorder; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Psychiatric Status Rating Scales; Psychotic Disorders | 2007 |